Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
Performance report of the audit committee in 2021
In accordance with the standards for the governance of listed companies issued by China Securities Regulatory Commission, the guidelines for the self-discipline supervision of companies listed on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation, the Listing Rules of shares on the science and Innovation Board of Shanghai Stock Exchange and other laws, regulations and normative documents, as well as the relevant provisions of the articles of association and the working system of the audit committee of the board of directors of the company, in 2021, The audit committee of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as “the company”) has actively carried out various work and earnestly performed relevant responsibilities based on the principle of diligence. Now the performance of the audit committee in 2021 is reported as follows:
1、 Basic information of the audit committee
During the reporting period, since Mr. Ma Guoqiang, the former member of the audit committee of the third session of the board of directors of the company, has resigned as a director and a member of the corresponding special committee of the board of directors, after deliberation at the first meeting of the fourth session of the board of directors of the company, the members of the audit committee of the board of directors of the company were adjusted to be independent director Mr. Jin Yongli, independent director Mr. Huang DUI and director Mr. Chen Yongfu. The tenure of the above members is the same as that of other directors of the current board of directors of the company, Among them, the chairman is Mr. Jin Yongli.
2、 Meetings of the audit committee of the board of directors
In 2021, the audit committee of the board of directors actively performed the duties of the professional committee in accordance with the company law, the articles of association, the working system of the audit committee of the board of directors and other relevant provisions. During the reporting period, the audit committee of the board of directors of the company held 5 meetings, and all members attended the meeting. The details are as follows:
Meeting name, time and proposal
The third Audit Committee 1. Report of Ernst & Young Huaming Certified Public Accountants (special general partnership) on the audit in 2020 at the first meeting in 2021 on March 29, 2021
1. Proposal on the company’s 2020 financial final accounts report;
On March 30, 2021 of the third Audit Committee 2. Proposal on the financial budget report of the second meeting of the company in 2021;
3. Proposal on reappointment of the company’s audit institution in 2021
The third Audit Committee on April 26, 2021 1 1. About the company’s first meeting in 2021 and the third meeting in 2021
Proposal for Quarterly Report
1. Proposal on the annual report and summary of the third Audit Committee of the company in the first half of 2021;
The fourth meeting in 2021 on August 25, 2021 2. Proposal on the special report on the deposit and actual use of the company’s raised funds in the half year of 2021
1. Proposal on the 2021 audit plan of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. at the first meeting of the fourth audit committee firm (special general partnership) of Ernst & Young Huaming Certified Public Accountants on December 21, 2021
3、 Performance of the audit committee
1. Supervise and evaluate the work of external audit institutions
During the reporting period, the audit committee of the board of directors investigated and evaluated the audit work of Ernst & Young Huaming Certified Public Accountants (special general partnership), the company’s audit institution in 2021, and believed that the institution could carry out the audit work in strict accordance with the relevant national regulations and the requirements of the professional norms of certified public accountants, and issue objective and fair audit opinions in accordance with the principle of independence.
2. Guidance on internal audit of the company
In 2021, the audit committee of the board of directors of the company guided the company’s internal audit institutions to carry out their own work from a professional perspective, urged the company’s internal audit institutions to strictly implement the audit work plan, and put forward guiding suggestions for internal audit, which improved the effectiveness of internal audit.
3. Review and comment on the company’s financial report
In 2021, the audit committee of the board of directors reviewed the company’s financial report, widely communicated with the company’s management on the preparation and key issues of the financial report, and supervised the authenticity, accuracy and integrity of the company’s financial report from a professional perspective. The Audit Committee believes that the company’s financial report is true and accurate, and there are no major defects in the company’s internal control.
4. Guidance on the company’s internal control
In 2021, the audit committee of the board of directors of the company gave full play to the role of professional committees, actively promoted the construction of the company’s internal control system, urged the construction of the company’s internal control standard system, guided the Audit Department of the company to actively and steadily promote the construction of the company’s internal control standard system in combination with the actual situation of the company, so that the company’s internal control system can be effectively implemented.
5. Coordinate the communication between management, internal audit department and relevant departments and external audit institutions
During the reporting period, in order to better enable the management and internal audit department to fully and effectively communicate with Ernst & Young Huaming Certified Public Accountants (special general partnership), the audit committee of the board of directors of the company actively coordinated through multiple channels, fully listened to the opinions of all parties, improved the efficiency of audit work and jointly played the function of audit supervision.
4、 Overall evaluation
During the reporting period, we performed the responsibilities and obligations of the audit committee of the board of directors with due diligence in accordance with the self regulatory guidelines for companies listed on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation and the working system of the audit committee of the board of directors formulated by the company.
In 2022, we will continue to adhere to the working principles of independence, objectivity and professionalism, combined with the actual business development needs of the company, actively pay attention to the production and operation status, urge and guide the internal audit department of the company to continue to optimize the internal audit business, maintain full communication with external audit institutions, provide advice and suggestions for the board of directors, give full play to the important responsibilities of the audit committee of the board of directors, and promote the compliance, stability and Healthy operation.
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. board of directors audit committee March 28, 2022 (no text below, signature page)
